Perindopril/indapamide

Drug Profile

Perindopril/indapamide

Alternative Names: Biprel; Coversyl Arginine Plus; Coversyl Plus; DW 7950; Indapamide/perindopril; Perigard-D; perindopril + indapamide; Predonium; Predonium DS; Preterax; S 5590

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Servier
  • Class Antihypertensives; Indoles; Sulfonamides
  • Mechanism of Action ACE inhibitors; Diuretics
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Hypertension

Most Recent Events

  • 19 Jun 2008 Efficacy data from a Phase-III trial (ADVANCE) in Hypertension presented at the 18th European Meeting on Hypertension (ESH-2008)
  • 17 Oct 2006 CV Therapeutics has terminated its licence for perindopril/indapamide in the US
  • 31 Mar 2006 Launched for Hypertension in New Zealand (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top